| Sharla Brown, APRN-CNS | |
|
5300 N Independence Ave Ste 280, Oklahoma City, OK 73112-5555 | |
| (405) 773-6400 | |
| (405) 621-5441 |
| Full Name | Sharla Brown |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 5300 N Independence Ave Ste 280, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821481789 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 90890 (Oklahoma) | Secondary |
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 90890 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Mercy Hospital Oklahoma City, Inc | Oklahoma city, OK | Hospital |
| Oklahoma Heart Hospital, Llc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oklahoma Nephrology Associates Inc | 7012998453 | 2 |
| Oklahoma Hospital Medicine Physicians Llc | 9830510023 | 110 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Entity Name | The Physicians Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487620381 PECOS PAC ID: 8325950603 Enrollment ID: O20031104000641 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Entity Name | Oklahoma Nephrology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407803380 PECOS PAC ID: 7012998453 Enrollment ID: O20040601000296 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Entity Name | Transit Medical Team Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205305737 PECOS PAC ID: 2264779909 Enrollment ID: O20190204000461 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Entity Name | Oklahoma Hospital Medicine Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871113761 PECOS PAC ID: 9830510023 Enrollment ID: O20200526000785 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sharla Brown, APRN-CNS 6516 N Olie Ave Ste G, Oklahoma City, OK 73116-7399 Ph: (405) 608-8060 | Sharla Brown, APRN-CNS 5300 N Independence Ave Ste 280, Oklahoma City, OK 73112-5555 Ph: (405) 773-6400 |
News Archive
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.
Scientists at the University of Massachusetts Medical School and the University of Texas at Austin have uncovered evidence that environmental influences experienced by a father can be passed down to the next generation, "reprogramming" how genes function in offspring. A new study published this week in Cell shows that environmental cues-in this case, diet-influence genes in mammals from one generation to the next, evidence that until now has been sparse.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 2 days ago
Jamie Louise Hunt, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young, Andrews Academic Tower, Suite 8400, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 405-271-5892 | |
Mrs. Janet Elizabeth Kristic, APRN CLINICAL NURSE Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1117 Nw 50th, Oklahoma City, OK 73118 Phone: 405-842-4435 Fax: 405-842-2846 | |
Todd J Ramer, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4300 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-752-3539 | |
Andrea Jeanne Mccoy, R.N. Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 4050 W Memorial Rd, Oklahoma City, OK 73120 Phone: 405-608-3800 Fax: 405-608-3838 | |
Shanelle Stensaas, APRN-CNS Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-613-3351 | |
Leighann Fullagar, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3300 Nw Expressway, Oklahoma City, OK 73112 Phone: 405-713-7403 Fax: 405-713-2794 | |
Michelle Tull, ACNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 800 Ne 10th St, Oklahoma City, OK 73104 Phone: 405-271-3402 |